Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status

Molecular Oncology

Volumn 6, Issue 1, 2012, Pages 88-97

  Nielsen, Kirsten Vang ^a   Ejlertsen, Bent ^b,c   Møller, Susanne ^c   Jensen, Maj Britt ^c   Balslev, Eva ^d   Müller, Sven ^a   Knoop, Ann ^e   Mouridsen, Henning T ^b,c  

^a AGILENT TECHNOLOGIES   (United States)

^b Rigshospitalet   (Denmark)

^c Danish Breast Cancer Cooperative Group (DBCG) Registry   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aneuploidy; Centromere 17; HER2; Ploidy level; Polysomy; TOP2A

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PARAFFIN; TOP2A PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GRADING; CELL NUCLEUS; CENTROMERE; CONTROLLED STUDY; DIPLOIDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENETIC ASSOCIATION; HAPLOIDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PLOIDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TETRAPLOIDY; TISSUE MICROARRAY; TREATMENT RESPONSE; TRIPLOIDY;

EID: 84856269278     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2011.11.006     Document Type: Article

References (52)

1. Archange C., Nowak J., Garcia S., Moutardier V., Calvo E.L., Dagorn J.C., Iovanna J.L. The WSB1 gene is involved in pancreatic cancer progression. PLoS ONE 2008, 3:e2475.
2. Bartlett J.M., Campbell F.M., Mallon E.A. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?. Am. J. Clin. Pathol. 2008, 130:920-926.
3. Bartlett J.M., Munro A., Cameron D.A., Thomas J., Prescott R., Twelves C.J. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J. Clin. Oncol. 2008, 26:5027-5035.
4. Bartlett J.M., Munro A.F., Dunn J.A., McConkey C., Jordan S., Twelves C.J., Cameron D.A., Thomas J., Campbell F.M., Rea D.W., Provenzano E., Caldas C., Pharoah P., Hiller L., Earl H., Poole C.J. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010, 11:266-274.
5. Beser A.R., Tuzlali S., Guzey D., Dolek Guler S., Hacihanefioglu S., Dalay N. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol. Oncol. Res. 2007, 13:180-185.
6. Bolzer A., Kreth G., Solovei I., Koehler D., Saracoglu K., Fauth C., Muller S., Eils R., Cremer C., Speicher M.R., Cremer T. Three-dimensional maps of all chromosomes in human male fibroblast nuclei and prometaphase rosettes. PLoS Biol. 2005, 3:e157.
7. Bose S., Mohammed M., Shintaku P., Rao P.N. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J. 2001, 7:337-344.
8. Burrell R.A., Juul N., Johnston S.R., Reis-Filho J.S., Szallasi Z., Swanton C. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. J. Cell. Biochem. 2010, 111:782-790.
9. Corzo C., Bellosillo B., Corominas J.M., Salido M., Coll M.D., Serrano S., Albanell J., Sole F., Tusquets I. Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis. Tumor Biol. 2007, 28:221-228.
10. Dal Lago L., Durbecq V., Desmedt C., Salgado R., Verjat T., Lespagnard L., Ma Y., Veys I., Di Leo A., Sotiriou C., Piccart M., Larsimont D. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol. Cancer Ther. 2006, 5:2572-2579.
11. Dhesy-Thind B., Pritchard K.I., Messersmith H., O'Malley F., Elavathil L., Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res. Treat. 2008, 109:209-229.
12. Downey L., Livingston R.B., Koehler M., Arbushites M., Williams L., Santiago A., Guzman R., Villalobos I., Di Leo A., Press M.F. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin. Cancer Res. 2010, 16:1281-1288.
13. Downs-Kelly E., Yoder B.J., Stoler M., Tubbs R.R., Skacel M., Grogan T., Roche P., Hicks D.G. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am. J. Surg. Pathol. 2005, 29:1221-1227.
14. Dowsett M., Procter M., McCaskill-Stevens W., de Azambuja E., Dafni U., Rueschoff J., Jordan B., Dolci S., Abramovitz M., Stoss O., Viale G., Gelber R.D., Piccart-Gebhart M., Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J. Clin. Oncol. 2009, 27:2962-2969.
15. Ejlertsen B., Mouridsen H.T., Jensen M.B., Andersen J., Cold S., Edlund P., Ewertz M., Jensen B.B., Kamby C., Nordenskjold B., Bergh J. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur. J. Cancer 2007, 43:877-884.
16. Gennari A., Sormani M.P., Pronzato P., Puntoni M., Colozza M., Pfeffer U., Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl. Cancer Inst. 2008, 100:14-20.
17. Guano F., Pourquier P., Tinelli S., Binaschi M., Bigioni M., Animati F., Manzini S., Zunino F., Kohlhagen G., Pommier Y., Capranico G. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol. Pharmacol. 1999, 56:77-84.
18. Gudkov A.V., Zelnick C.R., Kazarov A.R., Thimmapaya R., Suttle D.P., Beck W.T., Roninson I.B. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3231-3235.
19. Hyun C.L., Lee H.E., Kim K.S., Kim S.W., Kim J.H., Choe G., Park S.Y. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J. Clin. Pathol. 2008, 61:317-321.
20. ISCN An International System for Human Cytogenetic Nomenclature 2009, Karger, Basel.
21. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., Schonau A., Gunnarsdottir K., Olsen K.E., Mouridsen H., Ejlertsen B. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005, 23:7483-7490.
22. Lal P., Salazar P.A., Ladanyi M., Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J. Mol. Diagn. 2003, 5:155-159.
23. Leo A.D., Desmedt C., Bartlett J.M., Piette F., Ejlertsen B., Pritchard K.I., Larsimont D., Poole C., Isola J., Earl H., Mouridsen H., O'Malley F.P., Cardoso F., Tanner M., Munro A., Twelves C.J., Sotiriou C., Shepherd L., Cameron D., Piccart M.J., Buyse M. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011, 12:1134-1142.
24. Ma Y., Lespagnard L., Durbecq V., Paesmans M., Desmedt C., Gomez-Galdon M., Veys I., Cardoso F., Sotiriou C., Di Leo A., Piccart M.J., Larsimont D. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin. Cancer Res. 2005, 11:4393-4399.
25. Marchio C., Lambros M.B., Gugliotta P., Di Cantogno L.V., Botta C., Pasini B., Tan D.S., Mackay A., Fenwick K., Tamber N., Bussolati G., Ashworth A., Reis-Filho J.S., Sapino A. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009, 219:16-24.
26. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 2005, 97:1180-1184.
27. Merola R., Mottolese M., Orlandi G., Vico E., Cognetti F., Sperduti I., Fabi A., Vitelli G., Cianciulli A.M. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur. J. Cancer 2006, 42:1501-1506.
28. Mitelman, F., 2008. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
29. Moelans C.B., de Weger R.A., van Diest P.J. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res. Treat. 2010, 120:1-7.
30. Nakopoulou L., Giannopoulou I., Trafalis D., Gakiopoulou H., Keramopoulos A., Davaris P. Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters. Appl. Immunohistochem. Mol. Morphol. 2002, 10:20-28.
31. Nielsen K.V., Ejlertsen B., Moller S., Jorgensen J.T., Knoop A., Knudsen H., Mouridsen H.T. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol. 2008, 47:725-734.
32. Nielsen K.V., Müller S., Poulsen T.S., Gabs S., Schonau A. Combined use of PNA and DNA for fluorescence. Peptide Nucleic Acids: Protocols and Applications 2004, 227-260. Horizon Bioscience, Norfolk. second ed. P.E. Nielsen (Ed.).
33. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levine M.N., Bramwell V.H., Andrulis I.L., Pritchard K.I. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 2009, 101:615-618.
34. Olsen K.E., Knudsen H., Rasmussen B.B., Balslev E., Knoop A., Ejlertsen B., Nielsen K.V., Schonau A., Overgaard J. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol. 2004, 43:35-42.
35. Orsetti B., Nugoli M., Cervera N., Lasorsa L., Chuchana P., Ursule L., Nguyen C., Redon R., du Manoir S., Rodriguez C., Theillet C. Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes. Cancer Res. 2004, 64:6453-6460.
36. Perez E.A., Reinholz M.M., Hillman D.W., Tenner K.S., Schroeder M.J., Davidson N.E., Martino S., Sledge G.W., Harris L.N., Gralow J.R., Dueck A.C., Ketterling R.P., Ingle J.N., Lingle W.L., Kaufman P.A., Visscher D.W., Jenkins R.B. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J. Clin. Oncol. 2010, 28:4307-4315.
37. Press M.F. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?. Am. J. Clin. Pathol. 2006, 126:673-674.
38. Press M.F., Finn R.S., Cameron D., Di Leo A., Geyer C.E., Villalobos I.E., Santiago A., Guzman R., Gasparyan A., Ma Y., Danenberg K., Martin A.M., Williams L., Oliva C., Stein S., Gagnon R., Arbushites M., Koehler M.T. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin. Cancer Res. 2008, 14:7861-7870.
39. Press M.F., Sauter G., Buyse M., Bernstein L., Guzman R., Santiago A., Villalobos I.E., Eiermann W., Pienkowski T., Martin M., Robert N., Crown J., Bee V., Taupin H., Flom K.J., Tabah-Fisch I., Pauletti G., Lindsay M.A., Riva A., Slamon D.J. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J. Clin. Oncol. 2011, 29:859-867.
40. Reinholz M.M., Bruzek A.K., Visscher D.W., Lingle W.L., Schroeder M.J., Perez E.A., Jenkins R.B. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009, 10:267-277.
41. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
42. Staaf J., Jonsson G., Ringner M., Vallon-Christersson J., Grabau D., Arason A., Gunnarsson H., Agnarsson B.A., Malmstrom P.O., Johannsson O.T., Loman N., Barkardottir R.B., Borg A. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010, 12:R25.
43. Tandon A.K., Clark G.M., Chamness G.C., Ullrich A., McGuire W.L. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol. 1989, 7:1120-1128.
44. Troxell M.L., Bangs C.D., Lawce H.J., Galperin I.B., Baiyee D., West R.B., Olson S.B., Cherry A.M. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am. J. Clin. Pathol. 2006, 126:709-716.
45. Vanden Bempt I., Van Loo P., Drijkoningen M., Neven P., Smeets A., Christiaens M.R., Paridaens R., De Wolf-Peeters C. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J. Clin. Oncol. 2008, 26:4869-4874.
46. Varga Z., Tubbs R.R., Wang Z., Sun Y., Noske A., Kradolfer D., Bosshard G., Jochum W., Moch H., Ohlschlegel C. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res. Treat. 2011.
47. Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J. Pathol. 2009, 219:1-2.
48. Wang S., Hossein Saboorian M., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S., Hynan L., Ashfaq R. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 2002, 15:137-145.
49. Watters A.D., Going J.J., Cooke T.G., Bartlett J.M. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res. Treat. 2003, 77:109-114.
50. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
51. Wolman S.R. Fluorescence in situ hybridization: a new tool for the pathologist. Hum. Pathol. 1994, 25:586-590.
52. Yeh I.T., Martin M.A., Robetorye R.S., Bolla A.R., McCaskill C., Shah R.K., Gorre M.E., Mohammed M.S., Gunn S.R. Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod. Pathol. 2009, 22:1169-1175.